PT  - JOURNAL ARTICLE
AU  - Lewis, Morag A.
AU  - Schulte, Jennifer
AU  - Matthews, Lois
AU  - Vaden, Kenneth I.
AU  - Steves, Claire J.
AU  - Williams, Frances M.K.
AU  - Schulte, Bradley A.
AU  - Dubno, Judy R.
AU  - Steel, Karen P.
TI  - Accurate phenotypic classification and exome sequencing allow identification of novel genes and variants associated with adult-onset hearing loss
AID  - 10.1101/2023.04.27.23289040
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.27.23289040
4099  - http://medrxiv.org/content/early/2023/04/29/2023.04.27.23289040.short
4100  - http://medrxiv.org/content/early/2023/04/29/2023.04.27.23289040.full
AB  - Adult-onset progressive hearing loss is a common, complex disease with a strong genetic component. Although to date over 150 genes have been identified as contributing to human hearing loss, many more remain to be discovered, as does most of the underlying genetic diversity. Many different variants have been found to underlie adult-onset hearing loss, but they tend to be rare variants with a high impact upon the gene product. It is likely that combinations of more common, lower impact variants also play a role in the prevalence of the disease.Here we present our exome study of hearing loss in a cohort of 532 older adult volunteers with extensive phenotypic data, including 99 older adults with normal hearing, an important control set. Firstly, we carried out an outlier analysis to identify genes with a high variant load in older adults with hearing loss compared to those with normal hearing. Secondly, we used audiometric threshold data to identify individual variants which appear to contribute to different threshold values. We followed up these analyses in a second cohort. Using these approaches, we identified genes and variants linked to better hearing as well as those linked to worse hearing.These analyses identified some known deafness genes, demonstrating proof of principle of our approach. However, most of the candidate genes are novel associations with hearing loss. While the results support the suggestion that genes responsible for severe deafness may also be involved in milder hearing loss, they also suggest that there are many more genes involved in hearing which remain to be identified. Our candidate gene lists may provide useful starting points for improved diagnosis and drug development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was primarily funded by the National Institutes of Health/National Institute on Deafness and Other Communication Disorders (P50 DC 000422) awarded to the Medical University of South Carolina and by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, NIH/NCATS Grant number UL1 TR001450. This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06 RR14516 from the NIH/NCRR. TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd, the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Medical University of South Carolina gave ethical approval for this work. The Ethics Committee at Guy's & St Thomas' Trust gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData availability: Access to the TwinsUK data used in this study may be requested through the TwinsUK registry at https://twinsuk.ac.uk/. The mouse single cell RNAseq data is publicly available at https://umgear.org/. De-identified datasets from the MUSC cohort are available to researchers upon request and completion of institutional data use agreements, as required by the Medical University of South Carolina. https://twinsuk.ac.uk/ https://umgear.org/